HBIO
Harvard Bioscience IncCompany with tickers: HBIO
CIK
1123494
CUSIP
416906204
Shares Outstanding
4,510,182
13F Activity (30d)
7 filings
7 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Katherine A. Eade | Class II Director | Appointed | 2026-06-02 |
| John Duke | Class II Director | Appointed | 2026-06-02 |